Literature DB >> 24430292

Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study.

Jorge Vicente1, Fabricio González-Andrade, Antonia Soriano, Ana Fanlo, Begoña Martínez-Jarreta, Blanca Sinués.   

Abstract

This study was designed to investigate the potential differences between Spaniards and Ecuadorian Mestizo people regarding CYP2C8, CYP2C9, and CYP2C19 genetic polymorphisms. DNA from 282 Spaniard and 297 Ecuadorian subjects were analyzed by either a previously reported pyrosequencing method (CY2C8*3, CYP2C9*2, CYP2C9*3, CYP2C19*2 and CYP2C19*3) or a nested PCR technique (CYP2C19*17). Whereas CYP2C19*17 allele distribution was higher in Ecuadorians than in Spaniards (P < 0.001) and the frequency of CYP2C19*3 was similar in these two populations (P > 0.05), the other allelic variants were detected at significantly lower frequencies in Ecuadorians than in Spaniards (P < 0.05). According to the diplotype distributions, the prevalence of the presumed CYP2C9 and CYP2C8 extensive metabolizers was higher in Ecuadorians than in Spaniards (P < 0.05). Individuals genotyped CYP2C19*1/*17 and *17/*17 who were considered as ultrarapid metabolizers were overrepresented in Ecuadorians in relation to Spaniards (P < 0.001). By contrast, among Ecuadorians no poor metabolizers (PMs) of either CYP2C8 or CYP2C9 were found and only two individuals were CYP2C19 PMs. These data are compatible with a higher CYP2C8, CYP2C9, and CYP2C19 activity in Mestizo Ecuadorians as opposed to Spaniards, which could imply differences in dosage requirements for drugs metabolized by these cytochromes and should also be considered in allele-disease association studies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24430292     DOI: 10.1007/s11033-013-2971-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  44 in total

1.  North African genes in Iberia studied by Y-chromosome DNA haplotype 5.

Authors:  G Lucotte; N Gérard; G Mercier
Journal:  Hum Biol       Date:  2001-10       Impact factor: 0.553

2.  Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.

Authors:  Maria Gabriella Scordo; Achille P Caputi; Concetta D'Arrigo; Giuseppina Fava; Edoardo Spina
Journal:  Pharmacol Res       Date:  2004-08       Impact factor: 7.658

3.  Genetic variations and haplotypes of CYP2C19 in a Japanese population.

Authors:  Hiromi Fukushima-Uesaka; Yoshiro Saito; Keiko Maekawa; Shogo Ozawa; Ryuichi Hasegawa; Hiroshi Kajio; Nobuaki Kuzuya; Kazuki Yasuda; Manabu Kawamoto; Naoyuki Kamatani; Kazuko Suzuki; Tatsuo Yanagawa; Masahiro Tohkin; Jun-Ichi Sawada
Journal:  Drug Metab Pharmacokinet       Date:  2005-08       Impact factor: 3.614

4.  CYP2C19 polymorphism and risk for essential tremor.

Authors:  Hortensia Alonso-Navarro; Carmen Martínez; Elena García-Martín; Julián Benito-León; Isabel García-Ferrer; Pilar Vázquez-Torres; Inmaculada Puertas; Tomás López-Alburquerque; José A G Agúndez; Félix Javier Jiménez-Jiménez
Journal:  Eur Neurol       Date:  2006-09-08       Impact factor: 1.710

5.  Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population.

Authors:  Katsuyoshi Sugimoto; Tsukasa Uno; Hiroshi Yamazaki; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2008-01-30       Impact factor: 4.335

6.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Authors:  Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Clin Pharmacol Ther       Date:  2006-01       Impact factor: 6.875

7.  High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases.

Authors:  A L Zackrisson; B Lindblom; J Ahlner
Journal:  Clin Pharmacol Ther       Date:  2009-11-11       Impact factor: 6.875

8.  The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.

Authors:  Carmen Martínez; Elena García-Martín; Gerardo Blanco; Francisco J G Gamito; José M Ladero; José A G Agúndez
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

9.  Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

Authors:  M G Scordo; E Aklillu; U Yasar; M L Dahl; E Spina; M Ingelman-Sundberg
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

10.  Mephenytoin hydroxylation in the Cuna Amerindians of Panama.

Authors:  T Inaba; L F Jorge; T D Arias
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

View more
  7 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.

Authors:  Rania Abdelhedi; Nouha Abdelmoula Bouayed; Suad Alfadhli; Leila Abid; Ahmed Rebai; Najla Kharrat
Journal:  J Genet       Date:  2015-12       Impact factor: 1.166

3.  High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor.

Authors:  María Barreda-Sánchez; Juan Buendía-Martínez; Guillermo Glover-López; Carmen Carazo-Díaz; María Juliana Ballesta-Martínez; Vanesa López-González; María José Sánchez-Soler; Lidya Rodriguez-Peña; Ana Teresa Serrano-Antón; Remedios Gil-Ferrer; Maria Del Carmen Martínez-Romero; Pablo Carbonell-Meseguer; Encarna Guillén-Navarro
Journal:  Orphanet J Rare Dis       Date:  2019-02-26       Impact factor: 4.123

4.  Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children.

Authors:  N Espinoza; J Galdames; D Navea; M J Farfán; C Salas
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

Review 5.  Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health.

Authors:  Yitian Zhou; Volker M Lauschke
Journal:  Hum Genet       Date:  2021-10-15       Impact factor: 5.881

6.  Study of the allelic variants CYP2C9*2 and CYP2C9*3 in samples of the Peruvian mestizo population

Authors:  Ángel Tito Alvarado; Ana María Muñoz; Berta Loja; Jessica Michiko Miyasato; Jorge Antonio García; Roberto Andrés Cerro; Luis Abel Quiñones; Nelson Miguel Varela
Journal:  Biomedica       Date:  2019-09-01       Impact factor: 0.935

Review 7.  Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19.

Authors:  Anne B Koopmans; Mario H Braakman; David J Vinkers; Hans W Hoek; Peter N van Harten
Journal:  Transl Psychiatry       Date:  2021-02-24       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.